Sucroferric oxyhydroxide is marketed in Australia as Velphoro.
Hyperphosphataemia Clinical criteria: Treatment Phase: Initiation and stabilisation The condition must not be adequately controlled by calcium, AND Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; OR The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy, AND The treatment must not be used in combination with any other non-calcium phosphate binding agents. Treatment criteria: Patient must be undergoing dialysis for chronic kidney disease.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Phosphate binding takes place by ligand exchange between hydroxyl groups and/or water and the phosphate ions throughout the physiological pH range of the gastrointestinal tract.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Plain-language explainer for family/guardians: sucroferric oxyhydroxide
What is this medicine? Sucroferric oxyhydroxide is a phosphate-binding medicine. It is used in adults with chronic kidney disease (CKD) who are on dialysis, and for hyperphosphataemia (too much phosphate in the blood).
Why is it used? It helps control the amount of phosphate in the blood. People with poorly working kidneys can build up too much phosphate, so this medicine helps lower and keep phosphate levels under control. It is not a cure — it works alongside dialysis and other care.
How does it work? In the gut, it binds to phosphate from food and body fluids by swapping hydroxyl/water groups
Sucroferric oxyhydroxide is marketed in Australia as Velphoro.
1 brand name is recorded against this substance from the TGA eBS Product Information repository. The full list is in the Also known as card.